GlassScriptPhysician profile
Anupama Raghuram
NPI 1033235338
$8,946.85
in general payments reported to CMS, 2019-2025
12 companies · $162 in 2025
The $162 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,191 · 2020: $188 · 2024: $3,405 · 2025: $162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,315 · Food and Beverage: $234 · Education: $18.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,315.42 |
| Food and Beverage | $234.29 |
| Education | $18.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $4,629.10 | 2019-2024 | Capvaxive |
| Gilead Sciences, INC. | $3,501.04 | 2019-2025 | |
| Astellas Pharma US INC | $262.85 | 2019 | |
| Insmed, INC. | $172.91 | 2019-2025 | Arikayce |
| Janssen Biotech, INC. | $96.93 | 2019-2020 | |
| Allergan, INC. | $72.78 | 2019-2020 | |
| Shionogi INC | $67.62 | 2025 | Fetroja |
| Pfizer INC. | $40.07 | 2019-2020 | |
| Tetraphase Pharmaceuticals, INC. | $38.15 | 2019 | |
| Melinta Therapeutics, LLC | $34.51 | 2020 | |
| Viiv Healthcare Company | $15.99 | 2019 | |
| Dynavax Technologies Corporation | $14.90 | 2024 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anupama Raghuram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.